Clinical Trial Design: Statistical Options/Challenges Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Welcome and Introduction to Vi3C

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Varsha Gandhi, PhD, on Ibrutinib

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

David A. Hyman, MD, JD, on Inclusive Shared Savings

Nov

Today In Oncology

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Related Videos

Welcome and Introduction to Vi3C

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Varsha Gandhi, PhD, on Ibrutinib

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

David A. Hyman, MD, JD, on Inclusive Shared Savings

New Computational Tool Shows Strong Accuracy in Predicting Cancer Drug Targets

Long-Term Survival With vs Without Postmastectomy Chest Wall Irradiation in Breast Cancer

Newly Diagnosed AL Amyloidosis FDA Grants Traditional Approval to Regimen

Curative Treatment After First-Line Immunotherapy Improves Survival in HCC

FDA Approves Selumetinib for Adults With NF1 With Symptomatic, Inoperable Plexiform Neurofibromas